Citius Pharmaceuticals Initiates $6 Million Direct Share Offering Under Nasdaq Regulations

Citius Pharmaceuticals Launches $6 Million Direct Offering

Citius Pharmaceuticals Inc., a biopharmaceutical firm focusing on innovative critical care products, has announced a registered direct offering targeted at raising $6 million. This strategic move allows the company to further support its burgeoning product pipeline, including its recently approved immunotherapy product, LYMPHIR.

Details of the Offering

Citius Pharma's offering involves the sale of approximately 3,973,510 shares of common stock priced at $1.51 per share. Alongside these shares, the company will also issue common warrants, allowing investors to purchase additional shares at an exercise price of $1.40 each. This structure highlights Citius Pharma's commitment to creating value for its shareholders while positioning itself for future growth in the biopharmaceutical sector.

Expected to close around October 21, 2025, the offering is contingent on meeting standard closing conditions, managed by exclusive placement agent H.C. Wainwright & Co. The gross proceeds from this offering will be allocated toward advancing the commercial launch of LYMPHIR, fulfilling regulatory and milestone payments, and spearheading various development initiatives across the company’s product candidates.

Supporting Product Development

The funds raised are critical as Citius Pharma prepares to launch LYMPHIR™, recently approved by the FDA for treating cutaneous T-cell lymphoma, marking a significant milestone in the company’s product development journey. Additionally, Citius's robust pipeline includes Mino-Lok®, an antibiotic solution for catheter-related bloodstream infections, and CITI-002 (Halo-Lido), which aims to alleviate hemorrhoid symptoms. With successful trials recently completed for both Mino-Lok and Halo-Lido, the company is on track to capitalize on these advancements.

In 2023, Mino-Lok met both its primary and secondary endpoints in a pivotal Phase 3 trial, bolstering the company’s position as a leader in innovative treatment options. The management team is actively engaging with the FDA to align on future steps necessary to bring these products to market, which further demonstrates Citius Pharma’s commitment to enhancing patient care.

Investment Considerations and Forward-Looking Statements

While the offering is structured through an effective shelf registration statement previously filed with the SEC, the company emphasizes that this announcement should not be construed as a direct solicitation to buy or sell securities. The biopharmaceutical landscape poses inherent risks, and potential investors are cautioned to carefully review Citius Pharma's historical performance and future projections as described in its SEC filings.

This announcement signifies an opportunistic approach to funding the innovation pipeline while adhering to regulatory requirements, a hallmark of Citius Pharmaceuticals’ strategic direction. As the company looks ahead, successful navigation through various regulatory landscapes and clinical trials will be essential to tap into the established market demand for its breakthrough therapies.

In summary, Citius Pharmaceuticals is at a pivotal moment, leveraging its offerings to generate necessary capital that will fuel ongoing and future clinical research and establish a stronger market presence. As the company moves forward, it remains poised to impact the lives of individuals suffering from serious health conditions through innovative biopharmaceutical solutions. For more information about Citius Pharmaceuticals and its offerings, visit their official website.